View Press Releases

Viral Vectors And Plasmid DNA Manufacturing Market is rising rapidly at 20.8%

July 19, 2022

The global Viral Vectors And Plasmid DNA Manufacturing market size is expected to reach around US$ 10.6 billion by 2030 from valued at US$ 3.2 billion in 2020 and is anticipated to grow at a CAGR of 20.8% during forecast period 2021 to 2030.

The growing demand for viral vectors and plasmid DNA for gene therapy has prompted leading market participants to introduce innovative and technologically advanced programs and technologies to increase plasmid DNA production. For instance, In April 2018, GE Healthcare Life Sciences announced the introduction of KUBio BSL 2, a prefabricated, modular bioprocessing facility for the manufacturing of viral vector-based vaccinations, oncolytic virus, and cell and gene therapies.

The government investments in the development of novel technologies and production facilities are expanding. For instance, in 2018, the Department for Business, Energy, and Industrial Strategy granted Cobra Biologics a US$ 3.4 million Industrial Strategy Challenge Fund grant for infrastructure investment to expand production capabilities and commercialization of DNA and viral vector products. As a result, growing government spending on research & development is likely to propel market expansion throughout the forecast period.

The market growth is being fueled by an increase in the global prevalence of cancer and the availability of sophisticated healthcare facilities. As per GLOBOCAN 2020, there have been 1,92,92,789 new cancer cases in 2020, with the number expected to rise to 2,88,87,940 by 2040.  Furthermore, suicide gene therapy, therapeutic gene vaccines, oncolytic virotherapy, and anti-angiogenesis are just a few of the gene therapy treatments that have been developed to treat a variety of tumors. Therefore, it will increase the demand for gene therapy and further boost market growth.

Report Highlights

  • The Adeno-associated virus (AAV) segment held the highest market share of 18.86% in 2021.
  • The downstream processing segment held the highest market share of 53.31% in 2021 owing to highly complex procedures carried out for polishing and purification of clinical grade final products.
  • The vaccinology segment held the highest market share of 24.76% in 2021. This is due to the widespread use of viral vectors in vaccine development due to their efficiency-related benefits.
  • The research institutes segment held the highest market share of 56.60% in 2021. The increasing involvement of scientific communities in gene and cell therapy research is expected to increase the demand for viral vectors owing to the high demand for vectors for conducting research.
  • The cancer segment held the highest market share of 37.28% in 2021.
  • North America dominated the global market with a share of 48.99% in 2021. Some of the major factors that have contributed to the large share of this regional market are the presence of a substantial number of centers and institutes that are engaged in the R&D of advanced therapies.
  • The Asia Pacific is estimated to be the fastest-growing region due to the rising patient population, increasing R&D activities in this field, and others.

Get Sample Copy@ https://www.visionresearchreports.com/report/sample/38284